RhumbLine Advisers’s Adaptimmune Therapeutics ADAP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.05K | Sell |
8,533
-9,780
| -53% | -$2.35K | ﹤0.01% | 3998 |
|
|
2025
Q1 | $3.6K | Sell |
18,313
-1,435
| -7% | -$282 | ﹤0.01% | 3941 |
|
|
2024
Q4 | $10.6K | Buy |
19,748
+588
| +3% | +$317 | ﹤0.01% | 3874 |
|
|
2024
Q3 | $18.2K | Buy |
19,160
+2,439
| +15% | +$2.32K | ﹤0.01% | 3825 |
|
|
2024
Q2 | $16.3K | Buy |
16,721
+9,599
| +135% | +$9.36K | ﹤0.01% | 3900 |
|
|
2024
Q1 | $11.3K | Buy |
7,122
+1,210
| +20% | +$1.91K | ﹤0.01% | 3847 |
|
|
2023
Q4 | $4.69K | Buy |
5,912
+330
| +6% | +$262 | ﹤0.01% | 3991 |
|
|
2023
Q3 | $4.35K | Hold |
5,582
| – | – | ﹤0.01% | 4007 |
|
|
2023
Q2 | $5.16K | Buy |
+5,582
| New | +$5.16K | ﹤0.01% | 4072 |
|